Methotrexate is a widely used chemotherapeutic and immunosuppressive agent, requiring precise and accurate monitoring to ensure therapeutic efficacy while minimizing toxicity. The ARK Methotrexate Assay has been a well-established analytical method for the accurate determination of methotrexate concentrations in patient samples.

Building upon its proven performance, the next-generation ARK Methotrexate II Assay introduces advancements in sensitivity, precision, and linearity, delivering a more robust diagnostic tool for clinical laboratories. This next-generation assay provides refined precision and accuracy across its expanded assay range. The ARK Methotrexate II Assay surpasses its predecessor with increased sensitivity, allowing for more accurate measurements at both low and high concentrations, as well as improved recovery within the 0.500 to 1.000 μmol/L range.

Additionally, the assay demonstrates improved linearity, offering more consistent results while maintaining a proportional response across the entire assay range. Designed to provide superior measurement accuracy across an expanded assay range, the ARK Methotrexate II Assay strengthens the reliability of methotrexate monitoring, supporting clinicians in making informed treatment decisions.